Open AccessNeurohormonal Blockade and Circulating Cardiovascular Biomarkers During Anthracycline Therapy in Breast Cancer Patients: Results From the PRADA (Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy) Study
Author(s) -
Gulati Geeta,
Heck Siri L.,
Røsjø Helge,
Ree Anne H.,
Hoffmann Pavel,
Hagve TorArne,
Norseth Jon,
Gravdehaug Berit,
Steine Kjetil,
Geisler Jürgen,
Omland Torbjørn
Publication year - 2017
Publication title -
journal of the american heart association
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.494
H-Index - 85
ISSN - 2047-9980
DOI - 10.1161/jaha.117.006513
Subject(s) - medicine , anthracycline , breast cancer , candesartan , brain natriuretic peptide , biomarker , cardiotoxicity , trastuzumab , natriuretic peptide , cardiology , oncology , epirubicin , troponin , metoprolol , cancer , heart failure , chemotherapy , angiotensin ii , myocardial infarction , blood pressure , biochemistry , chemistry
Anthracyclines are associated with cardiotoxic effects. Cardiovascular biomarkers may reflect myocardial injury, dysfunction, inflammation, and fibrosis and may precede and predict the development of left ventricular impairment. The aim of this study was to assess: (1) longitudinal change in circulating cardiovascular biomarkers, (2) the effect of metoprolol succinate and candesartan cilexetil on the biomarker response, and (3) the associations between on-treatment changes in biomarker concentrations and subsequent left ventricular dysfunction in patients with early breast cancer receiving anthracyclines.